Danaher is a cleaner way than Thermo Fisher to play an aging population. Its greater bioprocessing exposure ties it more directly to drug cost of goods. x.com 

Danaher's Masimo deal can create far more value than its high-single-digit Year 5 ROIC target suggests, because it pays a similar EBITDA multiple for a faster-compounding earnings stream. The target means about an 8% Year 5 unlevered FCF yield on the $9.9B entry EV. Counting cash generated and terminal value, with $125M cost and $50M revenue synergies, IRR could be about 22%, high teens even before synergies. The topline case is aggressive, but Danaher's DBS record supports the synergies. x.com  … Show more

Danaher's rebound looks like one to fade near $190 because bioprocessing, its bigger business, delivered disappointing sales and guidance. Weak trading in peers, with Repligen also lower, echoed that. A move from $165 to $190 in two days seems off; the initial flush may have been overdone, but it is hard to argue Danaher deserves to trade back at $200, where it entered earnings, after that bioprocessing commentary. x.com 

Danaher's AI-driven life-sciences expectations look excessive against its results. After a 44% rise since May on hopes AI would lift life sciences to unprecedented levels, it missed Q3 revenue and guided Q4 growth to just 4-5%. x.com 

The bioprocessing recovery and AI acceleration story for Danaher and Thermo Fisher is failing, as demand for their lab equipment turns out to be weaker than hoped. A real recovery looks more like a calendar 2027 event. x.com  x.com